Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Therapeutic Advances in Respiratory Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Braido, F.
Right arrow Articles by Canonica, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Braido, F.
Right arrow Articles by Canonica, G. W.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Asthma
*International Health
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Worldwide differences on the concept of control of asthma

Fulvio Braido

University of Genoa Allergy and Respiratory Diseases, Department of Internal Medicine, Pad. Maragliano, Largo R. Benzi 10, Genova 16132, Italy, fulvio.braido{at}unige.it

Giorgio Walter Canonica

University of Genoa Allergy and Respiratory Diseases, Department of Internal Medicine, Pad. Maragliano, Largo R. Benzi 10, Genova 16132, Italy

Asthma is estimated to affect approximately 4—11% of the general population and its prevalence is increasing continuously. A large number of epidemiological studies on the prevalence of asthma and the level of disease control have been carried out, in which the level of control defined by GINA objectives was shown to be significantly unsatisfactory. Frequently, patients accept suboptimal levels of asthma control, mainly because they do not know how asthma is caused and how it can be treated. Apart from having a deep negative impact on patient's daily life, undiagnosed and undercontrolled asthma can also mean an increased economic burden. Therefore, greater attention should be paid to preventive measures, patient education and self-management programmes. Scientific evidence exists that drugs currently available can achieve all or almost all the objectives indicated by international guidelines in the majority of patients, and to improve patients' HRQL by minimizing the impact of the disease and its treatment from the patient's viewpoint. In conclusion, there is a gap between the level of control that could be reached and what is obtained in real life. This must be reduced through a series of interventions in which both doctor and patient are involved.

Therapeutic Advances in Respiratory Disease, Vol. 2, No. 1, 3-5 (2008)
DOI: 10.1177/1753465807087091


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement